Peter Weeke1, Jonathan D Mosley2, David Hanna3, Jessica T Delaney2, Christian Shaffer2, Quinn S Wells2, Sara Van Driest4, Jason H Karnes2, Christie Ingram2, Yan Guo5, Yu Shyr5, Kris Norris2, Prince J Kannankeril4, Andrea H Ramirez2, Joshua D Smith3, Elaine R Mardis6, Deborah Nickerson3, Alfred L George7, Dan M Roden8. 1. Department of Medicine, Vanderbilt University, Nashville, Tennessee; Department of Cardiology, Copenhagen University Hospital, Gentofte, Denmark. 2. Department of Medicine, Vanderbilt University, Nashville, Tennessee. 3. Department of Genome Sciences, University of Washington, Seattle, Washington. 4. Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee. 5. Vanderbilt Technologies for Advanced Genomics Analysis and Research Design, Nashville, Tennessee. 6. The Genome Institute, Washington University, St. Louis, Missouri. 7. Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee. 8. Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee. Electronic address: dan.roden@vanderbilt.edu.
Abstract
OBJECTIVES: The aim of this study was to test the hypothesis that rare variants are associated with drug-induced long QT interval syndrome (diLQTS) and torsades de pointes. BACKGROUND: diLQTS is associated with the potentially fatal arrhythmia torsades de pointes. The contribution of rare genetic variants to the underlying genetic framework predisposing to diLQTS has not been systematically examined. METHODS: We performed whole-exome sequencing on 65 diLQTS patients and 148 drug-exposed control subjects of European descent. We used rare variant analyses (variable threshold and sequence kernel association test) and gene-set analyses to identify genes enriched with rare amino acid coding (AAC) variants associated with diLQTS. Significant associations were reanalyzed by comparing diLQTS patients with 515 ethnically matched control subjects from the National Heart, Lung, and Blood Grand Opportunity Exome Sequencing Project. RESULTS: Rare variants in 7 genes were enriched in the diLQTS patients according to the sequence kernel association test or variable threshold compared with drug-exposed controls (p < 0.001). Of these, we replicated the diLQTS associations for KCNE1 and ACN9 using 515 Exome Sequencing Project control subjects (p < 0.05). A total of 37% of the diLQTS patients also had 1 or more rare AAC variants compared with 21% of control subjects (p = 0.009), in a pre-defined set of 7 congenital long QT interval syndrome (cLQTS) genes encoding potassium channels or channel modulators (KCNE1, KCNE2, KCNH2, KCNJ2, KCNJ5, KCNQ1, AKAP9). CONCLUSIONS: By combining whole-exome sequencing with aggregated rare variant analyses, we implicate rare variants in KCNE1 and ACN9 as risk factors for diLQTS. Moreover, diLQTS patients were more burdened by rare AAC variants in cLQTS genes encoding potassium channel modulators, supporting the idea that multiple rare variants, notably across cLQTS genes, predispose to diLQTS.
OBJECTIVES: The aim of this study was to test the hypothesis that rare variants are associated with drug-induced long QT interval syndrome (diLQTS) and torsades de pointes. BACKGROUND: diLQTS is associated with the potentially fatal arrhythmia torsades de pointes. The contribution of rare genetic variants to the underlying genetic framework predisposing to diLQTS has not been systematically examined. METHODS: We performed whole-exome sequencing on 65 diLQTS patients and 148 drug-exposed control subjects of European descent. We used rare variant analyses (variable threshold and sequence kernel association test) and gene-set analyses to identify genes enriched with rare amino acid coding (AAC) variants associated with diLQTS. Significant associations were reanalyzed by comparing diLQTS patients with 515 ethnically matched control subjects from the National Heart, Lung, and Blood Grand Opportunity Exome Sequencing Project. RESULTS: Rare variants in 7 genes were enriched in the diLQTS patients according to the sequence kernel association test or variable threshold compared with drug-exposed controls (p < 0.001). Of these, we replicated the diLQTS associations for KCNE1 and ACN9 using 515 Exome Sequencing Project control subjects (p < 0.05). A total of 37% of the diLQTS patients also had 1 or more rare AAC variants compared with 21% of control subjects (p = 0.009), in a pre-defined set of 7 congenital long QT interval syndrome (cLQTS) genes encoding potassium channels or channel modulators (KCNE1, KCNE2, KCNH2, KCNJ2, KCNJ5, KCNQ1, AKAP9). CONCLUSIONS: By combining whole-exome sequencing with aggregated rare variant analyses, we implicate rare variants in KCNE1 and ACN9 as risk factors for diLQTS. Moreover, diLQTS patients were more burdened by rare AAC variants in cLQTS genes encoding potassium channel modulators, supporting the idea that multiple rare variants, notably across cLQTS genes, predispose to diLQTS.
Authors: Stefan Kääb; Dana C Crawford; Moritz F Sinner; Elijah R Behr; Prince J Kannankeril; Arthur A M Wilde; Connie R Bezzina; Eric Schulze-Bahr; Pascale Guicheney; Nanette H Bishopric; Robert J Myerburg; Jean-Jacques Schott; Arne Pfeufer; Britt-Maria Beckmann; Eimo Martens; Taifang Zhang; Birgit Stallmeyer; Sven Zumhagen; Isabelle Denjoy; Abdennasser Bardai; Isabelle C Van Gelder; Yalda Jamshidi; Chrysoula Dalageorgou; Vanessa Marshall; Steve Jeffery; Saad Shakir; A John Camm; Gerhard Steinbeck; Siegfried Perz; Peter Lichtner; Thomas Meitinger; Annette Peters; H-Erich Wichmann; Christiana Ingram; Yuki Bradford; Shannon Carter; Kris Norris; Marylyn D Ritchie; Alfred L George; Dan M Roden Journal: Circ Cardiovasc Genet Date: 2011-11-18
Authors: Yalda Jamshidi; Ilja M Nolte; Chrysoula Dalageorgou; Dongling Zheng; Toby Johnson; Rachel Bastiaenen; Suzanne Ruddy; Daniel Talbott; Kris J Norris; Harold Snieder; Alfred L George; Vanessa Marshall; Saad Shakir; Prince J Kannankeril; Patricia B Munroe; A John Camm; Steve Jeffery; Dan M Roden; Elijah R Behr Journal: J Am Coll Cardiol Date: 2012-06-06 Impact factor: 24.094
Authors: Ping Yang; Hideaki Kanki; Benoit Drolet; Tao Yang; Jian Wei; Prakash C Viswanathan; Stefan H Hohnloser; Wataru Shimizu; Peter J Schwartz; Marshall Stanton; Katherine T Murray; Kris Norris; Alfred L George; Dan M Roden Journal: Circulation Date: 2002-04-23 Impact factor: 29.690
Authors: E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins Journal: N Engl J Med Date: 2008-07-23 Impact factor: 91.245
Authors: Peter Weeke; Jessica Delaney; Jonathan D Mosley; Quinn Wells; Sara Van Driest; Kris Norris; Gayle Kucera; Tanya Stubblefield; Dan M Roden Journal: Europace Date: 2013-06-19 Impact factor: 5.214
Authors: Zhenjiang Yang; Joseph K Prinsen; Kevin R Bersell; Wangzhen Shen; Liudmila Yermalitskaya; Tatiana Sidorova; Paula B Luis; Lynn Hall; Wei Zhang; Liping Du; Ginger Milne; Patrick Tucker; Alfred L George; Courtney M Campbell; Robert A Pickett; Christian M Shaffer; Nagesh Chopra; Tao Yang; Bjorn C Knollmann; Dan M Roden; Katherine T Murray Journal: Circ Arrhythm Electrophysiol Date: 2017-04
Authors: Conor M Lane; John R Giudicessi; Dan Ye; David J Tester; Ram K Rohatgi; J Martijn Bos; Michael J Ackerman Journal: Heart Rhythm Date: 2018-04-03 Impact factor: 6.343
Authors: David G Strauss; Jose Vicente; Lars Johannesen; Ksenia Blinova; Jay W Mason; Peter Weeke; Elijah R Behr; Dan M Roden; Ray Woosley; Gulum Kosova; Michael A Rosenberg; Christopher Newton-Cheh Journal: Circulation Date: 2017-02-17 Impact factor: 29.690
Authors: Megan Li; Flora Mulkey; Chen Jiang; Bert H O'Neil; Bryan P Schneider; Fei Shen; Paula N Friedman; Yukihide Momozawa; Michiaki Kubo; Donna Niedzwiecki; Howard S Hochster; Heinz-Josef Lenz; James N Atkins; Hope S Rugo; Susan Halabi; William Kevin Kelly; Howard L McLeod; Federico Innocenti; Mark J Ratain; Alan P Venook; Kouros Owzar; Deanna L Kroetz Journal: Clin Cancer Res Date: 2018-06-05 Impact factor: 12.531
Authors: Henry R Kranzler; Rachel V Smith; Robert Schnoll; Afaf Moustafa; Emma Greenstreet-Akman Journal: Addiction Date: 2017-04-21 Impact factor: 6.526